{"result": "(\"entity\"<|>SEMAGLUTIDE<|>ORGANIZATION<|>Semaglutide is a medication used in the treatment of type 2 diabetes, administered once weekly via subcutaneous injection.)\n##\n(\"entity\"<|>LIRAGLUTIDE<|>ORGANIZATION<|>Liraglutide is a medication that is added to metformin for patients with diabetes, known for its efficacy and safety.)\n##\n(\"entity\"<|>SUSTAIN TRIALS<|>EVENT<|>The SUSTAIN trials are a series of clinical studies evaluating the efficacy of semaglutide in treating type 2 diabetes.)\n##\n(\"entity\"<|>BARIATRIC SURGERY<|>EVENT<|>Bariatric surgery refers to various surgical procedures performed on the stomach or intestines to induce weight loss.)\n##\n(\"entity\"<|>ARODA VR<|>PERSON<|>Aroda VR is a researcher involved in studies related to diabetes treatments, including the SUSTAIN trials.)\n##\n(\"entity\"<|>PRATLEY RE<|>PERSON<|>Pratley RE is a researcher who contributed to the SUSTAIN 7 trial comparing semaglutide and dulaglutide.)\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>JAMA is a peer-reviewed medical journal that publishes research and reviews in the field of medicine.)\n##\n(\"entity\"<|>DIABETES METAB<|>ORGANIZATION<|>Diabetes Metabolism is a journal that focuses on research related to diabetes and its complications.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support refers to the dietary management and supplementation provided to patients post-surgery.)\n##\n(\"entity\"<|>GASTRIC BYPASS<|>EVENT<|>Gastric bypass is a type of bariatric surgery that helps patients lose weight by changing how the stomach and small intestine handle food.)\n##\n(\"entity\"<|>DERIVACIÓN BILIOPANCREÁTICA<|>EVENT<|>Derivación biliopancreática is a surgical technique used in bariatric surgery to aid in weight loss.)\n##\n(\"relationship\"<|>SEMAGLUTIDE<|>SUSTAIN TRIALS<|>Semaglutide was evaluated in the SUSTAIN trials for its effectiveness in treating type 2 diabetes<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDE<|>DIABETES METAB<|>Liraglutide's efficacy and safety were analyzed in a meta-analysis published in Diabetes Metabolism<|>7)\n##\n(\"relationship\"<|>BARIATRIC SURGERY<|>NUTRITIONAL SUPPORT<|>Nutritional support is critical for patients undergoing bariatric surgery to ensure proper recovery<|>9)\n##\n(\"relationship\"<|>PRATLEY RE<|>SUSTAIN TRIALS<|>Pratley RE was involved in the SUSTAIN 7 trial, which compared semaglutide to dulaglutide<|>8)\n##\n(\"relationship\"<|>AROADA VR<|>SUSTAIN TRIALS<|>Aroda VR contributed to the SUSTAIN trials, focusing on the treatment of type 2 diabetes<|>8)\n##\n(\"relationship\"<|>BARIATRIC SURGERY<|>GASTRIC BYPASS<|>Gastric bypass is one of the procedures classified under bariatric surgery<|>10)\n##\n(\"relationship\"<|>DERIVACIÓN BILIOPANCREÁTICA<|>BARIATRIC SURGERY<|>Derivación biliopancreática is a specific type of bariatric surgery aimed at weight loss<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: la dosis de 1 mg y 1,75 mg, el descenso de HbA1c fue -1,8% vs. -1,4% y el peso -6,5 kg                                                       denal en un asa (SADI-S) o a un bypass gástrico distal.\n         vs. -3,0 kg (p < 0,0001), respectivamente.                                                                                                      Si la técnica elegida o con experiencia para el cirujano es la derivación biliopancreática de\n         Referencias:                                                                                                                                    Scopinaro (con o sin preservación gástrica) debe realizarse en un solo gesto quirúrgico.\n         • Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with               Con estas      técnicas de derivación         biliopancreática se consiguen             pérdidas    del  40-50% del\n           once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab.\n           2019. doi: 10.1016/j.diabet.2018.12.001. [Epub ahead of print]                                                                                peso inicial y una remisión de las comorbilidades entre el 80% y el 95% de los casos.\n         • Gu J, Meng X, Guo Y, Wang L, Zheng H, Liu Y, et al. The efficacy and safety of liraglutide added to metformin in patients with diabetes:\n           a meta-analysis of randomized controlled trials. Sci Rep. 2016;6:32714.                                                                       Referencias:\n         • Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, et al. SUSTAIN 7 investigators. Semaglutide versus dulaglu-            • Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and metaanalysis.\n           tide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol.            JAMA. 2004;292:1724-37.\n           2018;6(4):275-86.                                                                                                                             • Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic\n                                                                                                                                                           review and meta-analysis, 2003-2012. JAMA Surg. 2014;149:275-87.\n\n\n\n     18  La paciente anterior no presenta contraindicaciones para la cirugía bariátrica.\n         Con vistas a plantear, junto con cirugía, la técnica quirúrgica a emplear,                                                                  19  Siguiendo con la paciente anterior, han pasado 5 días desde la cirugía, mantiene un\n         ¿cuál de las siguientes opciones recomendaría?                                                                                                  postoperatorio sin complicaciones y la tolerancia oral con dieta líquida (agua,\n                                                                                                                                                         manzanillas y caldos) ha sido correcta. Conociendo el tipo de cirugía bariátrica al\n         A. Derivación biliopancreática por cirugía abierta.                                                                                             que se la ha sometido, ¿qué decisión sobre el soporte nutricional tomaría usted?\n         B. Gastrectomía vertical por vía laparoscópica, como primer paso.                                                                               A. Continuar con la dieta líquida y prescribir nutrición parenteral periférica (NPP) para\n         C. Banda gástrica por vía laparoscópica.                                                                                                            garantizar el aporte adecuado de macro- y micronutrientes.\n         D.  Bypass gástrico proximal por vía laparoscópica.                                                                                             B. Iniciar una dieta de consistencia líquida artificial hiperproteica de muy bajo contenido\n                                                                                                                                                             calórico que garantice un aporte correcto de macro- y micronutrientes.\n         COMENTARIO                                                                                                                                      C. Colocar una sonda nasogástrica, para iniciar una dieta enteral hiperproteica\n         Como premisa, hoy en día no es aceptable realizar una cirugía bariátrica por vía abierta,                                                           normocalórica que garantice un aporte correcto de macro- y micronutrientes.\n         salvo que por condiciones de cirugías abdominales previas sea necesario. La vía lapa-                                                           D.  Iniciar una dieta de cocina (alimentación natural) de posgastrectomía.\n         roscópica reduce          significativamente        el  número de       complicaciones         posquirúrgicas,       las\n\n\n\n440                                                                                                                                                                                                                                                                                 441\n---\n                                                                                                                                                                                                                        OBESIDAD,              LÍPIDOS                     8\n                                                                                                                                                                                           Y TRASTORNOS ELECTROLÍTICOS\n\n\n\n     COMENTARIO                                                                                                                                8.2 Casos clínicos. Caso clínico 2\n     Los objetivos de la nutrición tras cirugía bariátrica son los de mantener un adecu\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}